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It is well establibsed that bS antibodies (BsAbs) can be used effectively in in the
ribosome-inactiing protein (RIP), saporn, against neopastic B cells. We have now extended this dely
system for use with eloin- By measuring antigen-binding caractristic and eptope mapping a panel of
antigelonin MAbs usmig the lAsys resonant mirror biesor, we were able to rapidly sdect the most suitable
for making BaAbs, The Fab' f ts from these MAbs were ly ugted with Fab' from cither
anti-CD22 or anti-CD38. Cytotoxicity assays showed that BsAbs wve highly efficient at delvering glonin to
cultured Daudi cells and achieved le of toxcity which coreatd dosely with the affinity of the BsAbs.
Using pairs of anti-CD22 BsAbs we were able to genrate bivalent BsAb-genmm complxs whch achived
IC valies of 2 x 10-" M geomn, a potency which is equivalent to that reache by saporin in this tag
system. However, beus geoin is 5-10tImes less toxic than saporin, the thrapeutic ratio for geloin is
superior, making it potentially a more useful agnt for human treatment Cytotoxicity assays and kinetic
anablsis showed that targeting geonin via CD38 was 2-5 tmes k effective than dlivy though CD22.
However, with a pair of BsAbs designed to c-arget lonin via CD22 and CD38, the cytotoxicity achived
equalEd that obtained with a pair of anti-CD22 BsAbs (IC"= 1 x 10-" M). This important result suggests
that the anti-CD38 helps bind the Fonin to the cell and is then 'dragged' or 'piggy-bcked' into the cel by
the anti-CD22 BsAb. The implication of these findings for cancer therapy is discussed.
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Bipecific antibodies (BsAbs) offer an exciting altemative to
conventional nimunotoxins (ITs) for the targeting of toxins,
such as ribosome-inactivating proteins (RIP), to neoplastic
cells (Raso and Griffin, 1981; Glenie 1988). Unlike ITs in
which the toxin is chemically conjugated directy to an
antibody molcule (Vitetta et al., 1987; Blakey and Thorpe,
1988), with BsAbs the RIP is held in one of the antigen
binding sites, while the second antigen-binding arm is used to
deliver the RIP to an appropriate target molecule on the
unwanted cell. The potential advantages of this targeting
systm include the avoiance of chemical modification of the
toxin or antibody and the ability to release the toxic moiety
from the antibody once inside the cell without the need to
reduce a disuphide bond. In addition, in certain situations it
may be possible to use BsAbs in a two-step delvery system
in which the BsAb is first and allowed to reach
maximum localisation ratio (tumour-normal tissue), before
giving the short-lived toxic moiety for capture by the
prelocalised antibody. This type of two-stage ddivery system
is being apphed very successfully to the radiom g of
tumours with BsAbs and radionulide (Peltier et al., 1993).
Clearly, the major disadvantage with the BsAb targeting
strategy is its relance on the comparatively weak non-
covalent interactions between the BsAbs and the toxin to
hold the complex together while it is delivered to the appro-
priate target.
We have shown previously that, in both leukaemic animals
(Glennie et al., 1988; French et al., 1991) and lymphoma
paients (Bonardi et al., 1992), bispecific F(ab% antibody
with dual specfiity for the RIP saporin and a tumour
marker can be highly efficient at delivering saporin and
eradicating tumour cells. However, optimal results are
achieved only if certain rules are followed: first, the BsAbs
must be used as complementary pairs of reagents which
recognise different, non-blocking, epitopes on the saporin
molecule and so provide bivalent attachment of the toxin to
the target cell (French et al., 1991); and, second, a tumour
marker must be slcted which is capable of transporting the
RIP inside the cell (Bonardi et al., 1993). To date we have
asessed the performance of BsAbs designed to deliver
saporin via a range of surface antigens on neoplastic B cells,
such as Ig, CD19, CD22 and CD37, and found that CD22 is
by far the most effcient in this respect (Bonardi et al., 1993).
In the present work we have developed a new panel of
BsAbs for the delivery of another type I RIP, gelonin. Like
saporin, gelonin is a singlchain type I RIP (Barbieri et al.,
1993). LD, studies in mice have shown that native gelonin is
approximately 10-fold less toxic than saporin (Battelli et al.,
1990), and so may be partcularly suitable for therapeutic
aplications. However, the results obtained with gelonin IT
have been variable and, while some derivatives have been
very effective at killing cells (Lambert et al., 1985; Sivam et
al., 1987), others have shown quite modest potency (Thorpe
et al., 1981; Bolognesi et al., 1992). The explanation for such
variation may lie, in part, in the sensitivity of gelonin to
chemical modification with the reagents used to introduce
sulphydryl groups for conjugation to the antibody (Thorpe et
al., 1981; Batteli et al., 1990; Bolognesi et al., 1992). For
example, Batteli et al. (1990) have reported that after disul-
phide bonding to IgG gelonin retains kss than 4% of its
original inhibitory activity in a reticulocyte lysate assay; this
compares with retention of 20% inhibitpry activity for an
equivalent saporin IT in this assay system. Better et al. (1994)
have recently reported that gelonin analogues with
egneered cysteine idues can form conjugates with higher
potency than those produced with linker-modified toxin. In
the light ofthese obsrvations we have investigated the use of
BsAbs, in which no chemical modification of the toxin is
required, for the delivery of gelonin to neoplastic cells.
MNterias and
Materials
The RIPs gelonin and saporin were purified from the seeds of
Geloniun madrflorum and Sainaria officalis, respectively,
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December 1994by water extraction as described previously (Stirpe et al.,
1980, 1983). BsAbs were tested on the Burkitt's lymphoma
cell line Daudi. These cells were maintained in suppklmented
RPMI-1640 [RPMI-1640 medium containing glutamine
(2 mM), pyruvate (1 mM), penicillin and streptomycin
(l00 IUml-'), fungizone (2 jg ml' ), ciprofloxacin
(10lgml-') and 10% fetal calf serum (FCS) (Myoclone;
Gibco, Paisley, UK)].
Monoclonal antibodies (MAbs) andbispecific antibody
(BsAb) derivatives
The following MAbs were used in this study: two anti-
saporin MAbs, anti-sap-I and anti-sap-5 (French et al.,
1991); anti-CD22 (D epitope), 4KB128, kindly provided by
Dr David Mason, John Radcliffe Hospital, Oxford, UK
(Mason et al., 1987); and the anti-CD38 MAb, AT13/5,
raised in this laboratory by immunising a mouse with the
Burkitt's lymphoma cell line Namalwa (J Elis et al., submit-
ted). Finally, six new anti-gelonin MAbs, anti-gel-I to -6,
were raised following immunisation of a Balb/c mouse with
gelonin and fusing its spleen cells with NS-1 myeloma cells
(Kohler and Milstein, 1965; Fazekas de St. Groth and
Scheidegger, 1980). Hybridoma cells secreting anti-gelonin
MAbs were identified by enzyme-linked immunosorbent
assay (ELISA) and cloned by limiting dilution in microcul-
ture plates.
All hybridoma lines secreting MAbs were expanded as
ascitic tumours in pristane-primed (Balb/c x CBA) F, mice
and the 7S IgG fraction isolated by precipitation in 2 M
ammonium sulphate followed by ion-exchange chromato-
graphy on Trisacryl-M-DEAE (Elliot et al., 1987). F(ab')2
fragments of IgG were prepared by limited proteolysis with
pepsin at pH 4.2 as described previously (Elliot et al., 1987;
Glennie et al., 1987). Heterodimeric F(ab')2 molecules
(BsAbs) containing two different mouse Fab' fragments were
constructed as described previously using the bis-maleimide
cross-linker, o-phenylenedimaniamide (Glennie et al., 1987,
1993).
Epitope mapping andantibody binding constants
Epitope mapping studies and antibody binding affinity deter-
minations were carried out using the lAsys resonant mirror
biosensor (IAsys; Fison's Applied Sensor Technology, Cam-
bridge) (Buckle et al., 1993; Cush et al., 1993). Gelonin
(50 Lg ml ' in 10 mM acetate buffer, pH 5.5) was coupled via
c-amino groups to the carboxymethylated dextran-sensing
surface [activated with l-ethyl-3-(3-dimethylaminopropyl)
carbodiimide/N-hydroxysuccinimideJ as described by George
et al. (1994) and Buckle et al. (1993). The coupling condi-
tions had been preoptimised with regard to pH, and led to
approximately 13-14 ngmm2 of the toxin being bound to
the dextran surface.
For epitope mapping studies, readings were taken every 2 s
(averaged reading of five data points taken 0.2 s apart). The
gelonin cuvette was equilibrated in phosphate-buffered saline
(PBS) containing 0.05% Tween (PBS-Tween). Monoclonal
antibodies, or their Fab' derivatives, were added to give a
final concentration of 20 Lg ml-', and their binding followed
for 25-30 min. After this time the binding was approaching
equilibrium, and the cuvette was washed four times rapidly
with PBS-Tween. A second MAb was then added to deter-
mine whether its binding was blocked by the first MAb. In
this way all possible pairs of the anti-gelonin MAbs were
compared. At the end of each experiment the cuvette was
regenerated by removing bound MAb with a 2 min wash in
50mM hydrochloric acid before re-equilibrating with
PBS-Tween.
For kinetic analysis the readings were taken every 0.2 s. To
follow the association of the MAbs with the immobilised
toxin, samples of anti-gelonin Fab' fragments were added to
the cuvette and allowed to bind for 5 min. The cuvette was
then washed four times with PBS-Tween, and the dissocia-
rsIouni ddel lumo ml nphom cebs
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tion followed for 5 min. The cuvette was regenerated as
described above.
Data were analysed using the FASTfit program (Fisons
Applied Sensor Technology) as described by George et al.
(1994). The association rate constant (k,) was determined by
fitting the association part of the data to the equation:
R = Ro + E(I1-e-k_)
where A? is the response, measured in arcseconds, at time t(s)
and Ro is the initial response. E is the extent of the change of
the response, and the kt, is the observed rate constant. kob is
related to k. by the equation:
kob, = k4AbI + kd,
where [Ab] is the concentration of MAb. Thus a plot of kob
against the concentration of Fab' should give a straight line
whose slope is k. and y-axis intercept is the dissociation rate
constant, kdi,.
The dissociation rate constants were calculated directly
from the dissociation reaction, by iterative fitting of the data
to the equation:
Rt = ROe - kdW
where R is the response at time t. The dissociation equili-
brium constant, Kd is defined as:
Kd = kdJkm
The data points fitted the theoretical curve for a single
binding site, typically to within 1-2 arcseconds, compared
with a typical maximum response of 300 arcseconds.
Incorporation of[3HJleucine by cultured Daudi cells
The incorporation of [3H]leucine into protein during short-
term culture of Daudi cells has been described previously
(French et al., 1991; Bonardi et al., 1993). Briefly, complexes
of BsAb and saporin were preformed for 1 h and then
incubated with Daudi cells (I05 per well) for 24 h at 3rC,
before pulsing overnight with 0.5pCi of [3H]eucine
(TRK.510, Amersham International, Amersham, UK). The
incorporation of [3H]leucine into cell protein was then
assessed by harvesting the cells onto glass microfibre filters
and washing with water. All experimental points on the
graph were determined in triplicate. The concentration of
saporin at which [3Hleucine uptake by cells was inhibited by
50% was taken as the IC50 value.
To determine the kinetics of protein synthesis inhibition,
100l I samples of BsAb and saporin at the appropriate con-
centration in supplemented leucine-free RPMI-1640 (Gibco)
were incubated for 1 h at 37C in 96-well microculture plates.
Daudi cells (3 x 105 per well) which had been preincubated
for 2 h in leucine-free medium at 37C were then added to
each well. Microculture plates were then transferred to 3rC
in a humidified atmosphere of 5% carbon dioxide in air and,
at the required time points, wells were pulsed with 1 pCi of
[H]leucine in 50pl of supplemented leucine-free RPMI-1640
for 30 min. Incorporation of [3H]leucine was stopped by the
addition of 30 d of a mixture of 5 mm cycloheximide and
20 mg ml-' L-leucine in PBS. At the end of the experiment,
the incorporation of[3HJleucine into cell protein was assessed
by harvesting as described above. Each time point was deter-
mined in triplicate and the results expressed as a percentage
of the incorporated counts obtained in cells incubated for the
same period in medium alone.
Radioiodination ofproteins
Saporin and gelonin were trace radiolabelled for binding
studies using carrier-free "2I (Amersham International,
Amersham, UK) and lodo-Beads (Pierce, Rockford, IL,
USA) as the oxidising reagent (Markwell, 1982). Radioac-
tivity was measured in a Rackgamma spectrometer (LKB).Giloin d6wyb I,phuna ceas
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Binding of[25I]saporin and['zIJgelonin to cell surfaces in the
presence ofBsAb
The binding of ['UI]saporin to the Daudi cell surface in the
presence of BsAb was investigated using a method based on
that described by Dower et al. (1981) and modified by
French et al. (1991). Radiolabelled saporin was serially
diluted and incubated as 1 ml aliquots with BsAb at
1 Lg ml-' in supplemented RPMI-1640 medium at 37C for
1 h to allow the formation of ['"IIsaporin-BsAb complexes.
A 100IlI volume of Daudi cells (final concentration 5 x I05
to 5 x 106 ml') was then added and the incubation con-
tinued for a further 1 h at 37C. Endocytosis of
saponn-BsAb complexes was prevented by inclusion of
sodium azide (15 mM) and 2-deoxyglucose (50 mM). The cells
were then separated from the aqueous phase by centrifuga-
tion through phthalate oils as described previously (French et
al., 1991).
Results
Generation ofanti-gelonin antibodies
In the current work six monoclonal anti-gelonin MAbs were
raised, anti-gel-l to anti-gel-6. Our previous investigations
using BsAbs to deliver saporin to lymphoma cells has shown
that selected pairs of BsAbs that recognise different epitopes
on saporin outperform single derivatives (French et al., 1991;
Bonardi et al., 1993). In order to identify pairs of MAbs
recognising different epitopes on the gelonin molecule, the
panel of anti-gelonin MAbs was epitope mapped using the
LAsys. This allows the interaction of molecules to be studied
in real time, thereby allowing rapid analysis of macro-
molecular interactions.
Epitope mapping was accomplished by immobilising the
antigen, gelonin, onto the dextran hydrogel that lies on top
of the sensing surface. A sample of one of the MAbs was
added to the cuvette and its binding followed until it was
close to equilibrium. A second MAb was then added to
determine whether it would bind to the gelonin in the
presence of the first MAb. A typical trace is shown in Figure
1, which demonstrates that the anti-gel-3 blocks the binding
of anti-gel-6 to gelonin, but not the binding of anti-gel-2 or
anti-gel-5. Table I shows the results of epitope mapping for
200 -
100 -
all six MAbs using such companrsons, demonstrating that the
panel of MAbs falls into three groups that do not cross-block
each other and therefore must recognise distinct epitopes on
gelonin.
Three MAbs, anti-gel-2, anti-gel-3 and anti-gel-5, one Ab
from each group, were selected for further analysis. The
kinetics of the interaction of their Fab' fragments with
gelonin were determined using the lAsys with the gelonin
immobilised to the sensing surface and the Fab' added to the
cuvette. The inset to Figure 2 shows a typical trace for Fab'
fragments from an anti-gelonin MAb, demonstrating the
association and dissociation phases of the reaction at three
different concentrations of MAb. When kj. is plotted against
antibody Fab' concentration (Figure 2), the slope of the
resulting straight line gives the k.. The kd. (also known as
the kff, kd or k-1) was determined directly from the dissocia-
tion phase of the data. Table II shows the km, kd, and K&
values obtained with Fab' fragments of the three anti-gelonin
MAbs used throughout the remainder of this paper. All three
MAbs had similar association rate constants, but there is a
10-fold difference in their dissociation rate constants, being in
the order anti-gel-5 <anti-gel-3 <anti-gel-2. Thus, the
derived Fab' dissociation equilibrium constants (Kd) were in
Table I Epitope mapping of anti-gelonin antibodies
First antibody
Second antibody Anti-gel-2 Anti-gel-3 Anti-gel-5
Anti-gel-I - + +
Anti-gel-2 - + +
Anti-gel-3 + - +
Anti-gel-4 + - +
Anti-gel-5 + + -
Anti-gel-6 + - +
Using the lAsys resonant mirror biosensor the first MAb was
allowed to bind for 25-30 min in the gelonin-coated cuvette. After
three washes in PBS-Tween, the second MAb was added to assess
whether it was able to bind (+) or was blocked (-), as described in
Figure 1. Three distinct, non-blocking, epitopes were identified
shown by anti-gel-2, anti-gel-3 and anti-gel-5.
co
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Fugwe 1 Epitope mapping ofanti-gelonin MAbs using the lAsys
system. Each of the four MAb Fab' fragments, anti-gel-3, -6, -2
and -5, was added sequentially to the gelonin-coupled sensing
surface as indicated (arrows) at a final concentration of
20 pg ml-' and their association followed. The result indicates
that the epitopes recognised by anti-gel-3, anti-gel-2 and anti-gel-
5 are independent and non-blocking, while the epitope recognised
by anti-gel-6 is almost completely blocked by anti-gel-3. A com-
plete breakdown of the epitope mapping for all the anti-gelonin
MAbs is given in Table I.
Antibody concentration (107 x M)
FIgwe 2 Determination of km and k&., for the anti-gel-2 MAb
using the resonant mirror biosensor. The association and dis-
sociation phases of Fab' anti-gel-2 binding to gelonin were
monitored at five concentrations over the range 0.25 x 10-7 M to
4 x 10-7M. For each MAb concentration investigated, the
association and dissociation phases were followed for 5 min fol-
lowed by a 2 min wash with 50 mm hydrochloric acid to remove
bound antibody. The inset shows the traces obtained at the three
highest concentrations: I, 4 x 10-7 M; II, 2 x 10-7 M; HI,
I X 10-7 M. The observed rate constant (ko) at each MAb con-
centration was determined using the FASTfit program. Main
figure: The plot of kl. against the MAb concentration gives a
straight line with a slope of km and an intercept with the y-axis
of kd,Gdoud. dsly b^Iniplm I ceo
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the order anti-gel-5<anti-gel-3<anti-gel-2, with anti-gel-5
having a 10-fold higher affinity than anti-gel-2. For com-
parison, Table II also shows the k. and kdj,, values for the
Fab' fragments of the two anti-saporin MAbs used in the
study, anti-sap-l and anti-sap-5. The kdE for the anti-saporin
MAbs are surprisingly rapid, being at least 2.5 times faster
than the equivalent values for the anti-gelonin MAbs. The
km for anti-sap-I is also high, and consequently the derived
Kd for this antibody almost equals that of the lowest affinity
anti-gelonin MAb, anti-gel-2. The km for anti-sap-5 is lower,
and consequently the Kd for Fab' from this MAb is ten times
lower than that of any of the other Fab's used in this study.
Cytotoxicity ofsaporin andgelonin delivered to Daud cells by
BsAb
Bispecific F(ab')2 antibodies were made by linking Fab'
fragments of the anti-gelonin MAbs with Fab' from anti-
CD22 (4KB128) or anti-CD38 (AT13/5) MAb using o-pheny-
lenedimaleimide. For comparison we used our most effective
targeting BsAbs, which were made by linking anti-saporin
MAbs (anti-sap-I and anti-sap-5) to anti-CD22 MAb
(French et al., 1991).
The ability of various BsAbs, either alone or in pairs, to
target the cytotoxcic activity of either gelonin or saporin to
Daudi cells in vitro is compared in Figure 3. Gelonin alone is
about 5- to 10-fold less toxic than saporin with an IC5,0 of
close to 10- M. A single BsAb binding to gelonin and CD22
increased this toxicity approximately 1000-fold to give an
IC50 of around 10-9 M. The efficacy of these single BsAbs
correlated with the affinity of the anti-gelonin MAbs used in
their construction, being in the order anti-gel-5>anti-gel-
3>anti-gel-2. For comparison, a single BsAb binding to
saporin and CD22 ([anti-sap-l x anti-CD22D was 8-fold
more active than the best anti-gelonin BsAb, giving an IC50
of I x 10-10 M. However, by far the most efficient delivery
system, as in previous work (French et al., 1991), was
obtained using pairs of BsAbs which had been selected to
recognise non-blocking epitopes on the gelonin molecule in
the epitope mapping studies described above. With the three
complementary combinations of BsAbs, anti-gel-2 + anti-gel-
3, anti-gel-3 + anti-gel-5 and anti-gel-2 + anti-gel-5, the IC50
is approximately 2 x 101I1 M, giving an approximately
50 000-fold increase in toxicity over gelonin alone. Figure 3
shows the result for [anti-gel-3 x anti-CD22] + [anti-gel-
5 x anti-CD22], which was typical of these pairs of
derivatives. This level of toxicity is very similar to that
achieved using a complementary pair of anti-saporin BsAbs
(Figure 3). Interestingly, however, despite giving similar IC_v
values, the inhibition of [3H]eucine incorporation achieved
with gelonin was never as complete as that obtained with
saporin, and even when gelonin was added at the highest
concentration the maximum inhibition achieved was only
90%, compared with the 98% inhibition seen with saporin.
Similar results were obtained when gelonin was targeted to
Daudi cells via CD38 (Figure 4a); however, the inhibition
achieved via CD38 was always less than with CD22. The
single anti-CD38 BsAbs, [anti-gel-3 x anti-CD381 and [anti-
gel-S x anti-CD381, and the cocktail of two anti-CD38 BsAbs
(anti-gel-3 and anti-gel-5) all have higher IC50 values than the
corresponding anti-CD22 derivatives and were unable to
inhibit completely protein synthesis at higher concentrations
of gelonin, with maximum inhibition of 60-70%. The assay
was repeated with an extended incubation time before the
addition of [3H]leucine, 48 h instead of 24 h, but the anti-
CD38 BsAbs still failed to achieve complete inhibition of
protein synthesis (results not shown). Using the IC50 values
alone, the CD38 derivatives are between 2- and 5-fold less
toxic than the equivalent CD22 reagents.
The flexibility of the BsAb delivery system makes simul-
taneous targeting of two surface antigens very straightfor-
ward, and in Figure 4b we show how a mixture of two
anti-gelonin-specific BsAbs, one directed to CD22 and the
other to CD38 (anti-gel-3 x anti-CD22J + [anti-gel-5 x anti-
CD38D, can be used to enhance delivery. Interestingly, with
this combination, and despite targeting through CD38, which
we have shown is not as efficient as CD22, gelonin toxicity at
least matches that obtained with a cocktail of anti-CD22
BsAbs (Figure 3b). Thus when gelonin is co-targeted to
CD22 and CD38 its cytotoxic profile assumes that of the
CD22 target.
Binding of['15I]RIP to Daudi cells in the presence ofBsAb
We next compared the number of gelonin and saporin
molecules delivered to Daudi cells by the various BsAbs. In
these experiments the radiolabelled RIP and BsAb were
allowed to bind to cells and then cell-bound and free ['"I]-
RIP were separated by rapid centrifugation of the cells
through a mixture of phthalate oils. The binding of ['5I]RIP
to Daudi cells was determined under the same conditions
(RIP concentration range and BsAb concentration) as those
used in the cytotoxicity assays (Figures 3 and 4). Figure 5a
shows the binding curves obtained using a single or a pair of
BsAbs to tether ['"I]gelonin or [('Ilsaporin via CD22. The
number of gelonin molecules delivered by the two single
anti-gelonin BsAbs, [anti-gel-3 x anti-CD22] and [anti-gel-
5 x anti-CD221, was higher than the number of saporin
molecules delivered by [anti-sap-l x anti-CD22J, with 15 000
and 23 000 molcules ofgelonin delivered at 3 x 10-9 M toxin
compared with 8000 molecules of saporin. The ability of
these single BsAbs to capture radiolabelled RIP correlates
closely with their measured binding constants given in Table
II. As expected, using a complementary pair of BsAbs in this
assay increased the avidity of binding considerably and
resulted in approximately 90 000 molecuks of ['"I]gelonin
1-5
Toxin (M)
Table H Kinetic binding constants for anti-gelonin antibodies
Antibody k,d (-'s-') k (s-') Kd (m)
Anti-gel-2 6.02 ± 0.07 x 104 8.19± 0.69 x 10-4 1.36 x 10-8
Anti-gel-3 5.03 ± 0.15 x 10' 3.03 ± 0.39 x 10-4 6.02 x 10-9
Anti-gel-5 5.66 ± 0.06 x 104 9.25 ± 1.55 x 10-5 1.63 x 10-9
Anti-sap-I 29.20 ± 1.14 x 104 5.43 ± 0.26 x 10-3 1.86 x 10-'
Anti-sap-5 1.62 ± 0.02 x 104 2.05 ± 0.15 x 10-3 1.27 x 10-7
The k, and kd. values of the Fab' fragments from the
anti-gelonin MAbs were determined as shown in Figure 2 using the
IAsys resonant mirror biosensor. The values for the anti-saporin
MAbs are taken from George et al. (1994).
Fge 3 Comparison of the cytotoxicity of saporin and gelonin
in the presence of anti-CD22 BsAb. Cells (5 x 105) were cultured
in suppklmented RPMI containing gelonin (solid lnes) or saponn
(dashed lines) at the concentrations shown and BsAb at 1 1zg ml-'
for 24 h at 3TC. The wells were then pulsed with 0.5 pCi of
[3HjIeucine for a further 16 h before havesting the cells and
determining the incorporation of radioactive counts. Gelonin
alone (0 0); saporin alone (x-x); [anti-gel-2 x anti-CD22]
(V V); [anti-gel-3 x anti-CD22J (O -O); [anti-gel-5 x
anti-CD22J (O 0); [anti-gel-3 x anti-CD22J + [anti-gel-5 x
anti-CD221 (U U); [anti-sap-I x anti-CD22J (A-A); [anti-
sap-I x anti-CD22] + [anti-sap-5 x anti-CD221 (A -A).
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Flgwe 4 Comparison of the cytotoxicity of gelonin targeted via
CD22 and CD38. Uptake of [H]leucne by Daudi cells was
measured as described in Figure 3. (a) Gelonin alone (0 *);
[anti-gel-3 x anti-CD38] (O-0); [anti-gel-5 x anti-CD38]
(O-0); [anti-gel-3 x anti-CD381 + [anti-gel-5 x anti-CD38]
(U - -); [anti-gel-5 x anti-D22] (0 O); and [anti-gel-
3 x anti-CD22] + [anti-gel-5 x anti-CD22] (U *). (b) Gelonin
alone (0 0); [anti-gel-5 x anti-CD38] (O- 0); [anti-gel-
3 x anti-CD221 (0 O); and [anti-gel-5 x anti-CD381 + [anti-
gel-3 x anti-CD22] (A A).
and 30 000 molecules of ['I]saporin binding to each cell at a
toxin concentration of 3 x 1O-9 M.
The results in Figure Sb show similar data for
radiolabelled gelonin binding to Daudi cells via anti-CD38
BsAb. In general, CD38-specific BsAbs capture between two
and three times more RIP than CD22 BsAb. This difference
reflects the increased level of CD38 expression on Daudi cells
(unpublished observations). As with the CD22-specific
reagents, we obtained a sizeable increase in avidity using a
pair of anti-CD38 BsAbs, allowing approxiimately 250 000
molecules of gelomnn to bind to each cell at 3 x 10-9 M toxin.
Figure Sb also shows that very similar levels of binding were
achieved when gelonin was tethered via CD38 alone using a
pair of CD38-specific BsAbs, or via CD38 and CD22 using a
combination of CD38- and CD22-specific BsAbs.
Using these binding data we were able to estimate, for
each BsAb and each combination of BsAbs, the number of
gelonin or saporin molecules bound to the target cells at their
respective IC50 values obtained in toxicity studies (Figures 3
and 4). The results are summarised in Table III. When
saporin is targeted via CD22, either with a single BsAb or
with a pair of BsAbs, approximately 1000 molecules of
saporin will be bound to the cell surface at the IC5o. In
contrast, to achieve an IC50 using gelonin, between 6000 and
10000 molecules are required at the cell surface. Comparing
the delivery of gelonin via CD22 and CD38 reveals a striking
difference in efficiency between the two target antigens. With
anti-CD38 BsAbs, either singly or in pairs, half-maximum
inhibition of protein synthesis was achieved only when
between 35 000 and 60 000 molecules of gelonin were bound
at the cell surface. With the combination of one BsAb
directed at CD22 and one BsAb directed at CD38, the
efficiency approached that obtained with single or pairs of
anti-CD22 BsAbs, with 12 000 molecules of gelonin bound at
the IC50 concentration.
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Fugwe 5 Binding of [12511gelonin and ['2I]saporin to Daudi cells
in the presence of anti-CD22- or anti-CD38-specific BsAbs. BsAb
(1 lLg ml-') was incubated with various concentrations of
[125IJRIP for I h at 3rC. Daudi cells (5 x 106) were then added
and the incubation continued for a further 1 h. Any endocytosis
of cell-bound complexes was inhibited by including 15 mm
sodium azide and 50mm 2-deoxyglucose. The cells were then
sedimented through phthalate oils and the pellet counted for
radioactivity. The results are expressed as the number of
molcules of gelonin or saporin bound per cell. (a) Binding via
CD22: gelonin + [anti-gel-3 x anti-CD22] (O-0); gelonin +
[anti-gel-5 x anti-CD221 (O 0); gelonin + [anti-gel-3 x anti-
CD221 + [anti-gel-5 x anti-CD22] (- U); saporin + [anti-
sap-5 x anti-CD22] (A A); and saporin + [anti-sap-l x anti-
CD22]+ [anti-sap-5 x anti-CD22] (A - A). Results show means +
s.ein. of three ts. (b) Binding via CD38 and CD38/CD22:
geoin + [anti-gel-3 x anti-CD38] (O -0); gelonin + [anti-gel-
5 x anti-CD38] (O -0 gekoin +[anti-gel-3 xanti-CD38] +
[anti-gel-5 x anti-CD38] ( -- ); and gelonin + [anti-gel-5 x anti-
CD38] + [anti-gel-3 x anti-CD22] (V V). Results show average
of two experiments.
Kinetics ofinhibition of[3HJleucine uptake
The rate at which gelonin and saporin inhibited [3Hjleucine
uptake into Daudi cells in the presence of BsAbs was
examined. A- range of concentrations of saporin and gelonin
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I(0.02-20 iLg ml- ) were investigated for each single or pair of
anti-CD22 BsAbs. The maximum rate of inhibition was
achieved when saporin or gelonin was included at a concen-
tration of 2 gig ml' or above (Figure 6a, inset). In all subse-
quent experiments RIPs were used at 2 gmg11. Figure 6a
(main figure) shows the rate of inhibition of [3Hpeucine
incorporation with CD22-specific BsAbs. In all cases there
was a lag period of at least 6 h before any inhibition was
recorded. When the inhibition of [3Hjeucine uptake did com-
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Fwe 6 The kinetics of gelonin and saporin toxicity in the
presence of BsAb. Daudi cells (5 x lIW) were incubated with
BsAb (I gig ml-') and gelonin or saporin at the required concent-
ration at 37C (see below). At seled intervals wells were pulsed
with I iLCi of [3Hpeucine for 30min and the incorporation stop-
ped by the addition of 30 id of 5 mM cycloheximide + 20 mg ml-'
L-kucine. At the end of the time course the cells were harvested
and the incorporation of radioactivity determined. (a) (gelonin
and saporin at 2 jig ml-l throughout) Gelonin + [anti-gel-
5 x anti-CD221 (O 0); gelonin + [anti-gel-3 x anti-CD221 +
[anti-gel-5 x anti-CD22] (U U): saporin + [anti-sap-I x anti-
CD221 (A A); and saporin + [anti-sap-I x anti-CD221 +
[anti-sap-5 x anti-CD22] (A A). Inset Single BsAb [anti-sap-
1 x anti-CD221 and saporin at: I, 0.02Mgml-'; II, 0.2jgml-i;
III, 2gigml-'; or IV, lOpgml-'. Similar results were obtained
with gelonin. Concentrations above 2pgml-' gave a maximum
rate of inhibition of [3H]leucine for both saporin and gelonin. (b)
(gelonin and saporin at 2 gg ml-' throughout) Gelonin + [anti-
gel-5 x anti-CD38] (O-0); gelonin + [anti-gel-3 x anti-CD38]
+ [anti-gel-5 x anti-CD381 (U
- U): and gelonin + [anti-gel-
5 x anti-CD381 + [anti-gel-3 x anti-CD221 (V V).
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mence, saporin was significantly more active than gelonin,
achieving 90% inhibition by 24 h. By extrapolation, gelonin
would have taken around 40 h to achieve this level of inhibi-
tion. Interestingly, the rate of inhibition was the same wheth-
er the toxin was delivered by a single BsAb or by a combina-
tion of BsAbs.
When gelonin is delivered via CD38 (Figure 6b), again we
see a long lag period before any inhibition of protein syn-
thesis can be measured. This is followed by even slower
kinetics for the inhibition of protein synthesis than when
gelonin was targeted via CD22, and by extrapolation
[3Hlleucine uptake would have taken around 60 h to be
reduced to 10% of the control level. However, one of the
most important findings from this work is that, when gelonin
is delivering via CD22 and CD38, using a mixed cocktail of
BsAbs, the rate of inhibition increases to that achieved with
anti-CD22 BsAbs. Thus, by delivering through two surface
antigens, we have increased the activity of the CD38
denrvative to that of the anti-CD22 BsAb.
Disussio
In the current work we have investigated anti-CD22- and
anti-CD38-specific BsAbs for the delivery of gelonin against
neoplastic B cells. Six new anti-gelonin MAbs were raised by
conventional MAb technology and then epitope mapped on
gelonin using the IAsys. The LAsys allowed rapid analysis of
the binding characteristics of the new MAbs and proved
extremely efficient at identifying MAbs which recognised
different, non-overlapping epitopes on gelonin. From the
panel of MAbs, three (anti-gel-2, -3 and-5) were selected as
recognising non-blocking epitopes on gelonin. The Kd of
these MAbs ranged from approximately 1 x 10' to
6 x 19-9M, with two MAbs, anti-gel-3 anti-gel-5, having
respectively three and ten times higher affinity than the best
of our anti-saporin MAbs, anti-sap-l (Table II). Interest-
ingly, one of us (AJTG) has shown that a major difference
between these anti-gelonin MAbs and a panel of our anti-
saporin MAbs is that in general the latter have strik-ingly
faster off-rates. The results in Table H show that the three
anti-gelonin MAbs have kdi values which are between 6 and
50 times slower than anti-sap-l. One possible explanation for
this disparity is that during an immune response, because
saporin is more toxic than gelonin, most responding B cells
may be kiled as a result ofinternalising even a small amount
of saporin via their surface Ig. However, those B cells which
express surface antibody with a very fast off-rate may engage
saporin briefly and achieve activation before the toxin has
been camed inside the cell (George et al., 1994).
For the current work, Fab' from anti-gel-2, -3 and -5 was
constructed into bispecific F(ab% antibodies with Fab' from
either anti-CD22 or anti-CD38 as their anti-B-cell arm. The
three anti-CD22 derivatives performed well in delivering
gelonin to Daudi cells and enhanced the toxicity of gelonin
between 400- and 2000-fold. As expected, targeting activity
showed a strong correlation with the affinity of the anti-
gelonin MAbs used in the construction of BsAbs. However,
we consistently found that, either as free RIP or when
delivered by a BsAb, the gelonin was significantly less toxic
than saporin. For example, gelonin delivered by the most
effective single BsAb, [anti-gel-5 x anti-CD22J, was 10-fold
less toxic than saporin delivered by [anti-sap-i x anti-CD221.
This difference was not due to the BsAb capturing less
gelonin on the cell surface, since binding experiments with
radiolabelled RIPs showed that the level of gelonin bound by
[anti-gel-5 x anti-CD22] was around 3-fold higher than that
of saporin bound by [anti-sap-I x anti-CD22], consistent
with anti-gel-5 having a higher affinity than anti-sap-I. By
combining the binding data with the results of the cytotox-
icity experiments, we found that, for gelonin delivered by a
single BsAb, half-maximum inhibition of protein synthesis
was not achieved until approximately 6000-10 000 molecules
were bound to each cell, while only 1000 molecules of
saporin per cell were required to reach this level of toxicity.
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Table m Summary of toxicity and binding study using BsAbs against CD22
and CD38 to deliver saporin and gelonin to Daudi cells
Molecules Fold
Derivative2 IC50b (MV) at IC9fc increased
Saponrn alone 3.6 + 1.0 x lo-,
Gelonin alone 1.7 ± 0.9 x 10-6
Anti-CD22 reagents (saporin)
[anti-sap-i x anti-CD22] 1.1 ± 0.2 x 10`0 1000 3600
[anti-sap-I x anti-CD22] +
[anti-sap-5 x anti-D22] 1.0 ± 0.2 x 10-" 1500 36000
Anti-CD22 reagents (gelonin)
[anti-gel-2 x anti-CD22] 4.4 ± 1.3 x 10-9 NIX 400
[anti-gel-3 x anti-CD22] 2.3 ± 0.9 x 10-9 10000 700
[anti-gel-5 x anti-CD22] 8.2 ± 0.3 x 10`0 9000 2100
[anti-gel-3 x anti-CD221 +
[anti-gel-5 x anti-CD22] 2.9 ± 1.3 x 10-" 6000 59000
Anti-CD38 reagents
[anti-gel-3 x anti-CD38] 3.9 ± 0.1 x 10-9 5000 400
[anti-gel-5 x anti-CD38] 1.6 ± 0.2 x 10-9 35000 1100
[anti-gel-3 x anti-CD38] +
[anti-gel-5 x anti-CD381 1.6 0.2 x 10-10 60000 10600
Anti-CD22 anti-CD38 cocktail
[anti-gel-3 x anti-CD22] +
[anti-gel-5 x anti-CD381 1.3 x 10-"1 12000 130800
'Antibody derivatives were either single or pairs of bispecific F(ab)
antibodies as indicated at I pLg ml-. The pairs of BsAbs were equal quantities
(0.5Spgml-) of the two indicated reagents which reacted with gelonin or
saporin through two different, non-blocking, epitopes. bRIP concentrations
giving half-maximum incorporation of [3HJleucine in cytotoxicity experiments
(see Figures 3 and 4). Each result shows the mean molar concentration and the
standard error obtained from three independent experiments, except for the
final result (cocktail of anti-CD22 and anti-CD38 BsAbs), which is the mean
IC50 obtained from two experiments. cAverage number of RIP molecules bound
per Daudi cell at the IC50 concentration taken from the binding studies (Figure
5). dFold increase in gelonin or saporin toxicity when incubated with BsAb as
compared with that for gelonin or saporin alone (values given to the nearest
100). 'Not determined.
Thus as a free molecule and when delivered by a BsAb,
gelonin is 5- to 10-fold less toxic than saporin to Daudi cells.
An explanation for the difference in toxicity between saporin
and gelonin may lie in the finding that, to achieve full
inactivation of ribosomes, gelonin requires a co-factor (Car-
nicelli et al., 1992) identified as RNA (Brigotti et al., 1994),
whereas saporin does not. It is possible that the lower tox-
icity of this RIP is due to a low level of this co-factor in
target cells.
Despite this difference in toxicity, when delivered by a
complementary pair of BsAbs, gelonin achieved an IC50
(2 x 10-" M) which was effectively equivalent to that given
by saporin (1.5 x 10-" M) (Figure 3 and Table III). Since we
have already established that gelonin is less toxic than
saporin, the explanation for such potency probably lies in the
very high avidity with which the selected pair of anti-gelonin
BsAbs captured gelonin at the cell surface. The binding data
support this conclusion, showing that, depite their similar
IC50 values, the pair of anti-gelonin BsAbs are binding ap-
proximately six times more RIP to each cell than are the
anti-saporin BsAbs. The implications of this result are very
important for patient treatment because it shows that with
the available mixtures of BsAbs the therapeutic ratio
(targeted toxicity/non-specific toxicity) of gelonin is greater
than that of saporin. Further studies are under way to
confirm this observation.
Previous work has shown that CD22 (Bonardi et al., 1993),
CD25 (Tazzari et al., 1993) and CD40 (unpublished observa-
tions) are highly effective targets for delivering BsAb-
saporin complexes into human neoplastic B cells. We have
found that a range of other surface molecules on B cells,
such as CD19, CD37 and Ig, were very poor, or completely
ineffective, at mediating transport of BsAb-saporin com-
plexes inside cells and augmenting inhibition of protein syn-
thesis (Bonardi et al., 1993). It is now evident that CD38 can
also be used to target RIP in this delivery system. However,
its performance, while much better than that of CDl9 and
CD37, is not as good as that of CD22. The IC_o values
achieved with anti-CD38 BsAbs were 2-10 times higher than
with equivalent anti-CD22 reagents, and most importantly
the toxicity curves often failed to reach the baseline, showing
that the inhibition of protein synthesis was not complete.
Binding data strongly suggest that, despite high levels of
expression, Daudi cells either internalise CD38 poorly or
deliver CD38-bound BsAb-RIP complexes to an inapprop-
riate compartment inside the cell which prevents efficient
translocation of RIPs into the cytosol. For example, between
35000 and 60 000 molecules of gelonin are needed on the
surface of each cell to achieve half-maximum inhibition of
protein synthesis. These values compare with 6000-10000
molecules per cell when gelonin is targeted via CD22 (Table
III). Similarly, the failure of anti-CD38 derivatives to block
protein synthesis completely and the relatively slow kinetics
of the inhibition probably reflect poor internalisation relative
to CD22.
Perhaps the most interesting finding to emerge from the
current work comes from using combinations of BsAbs
which engage two distinct cellular targets simultaneously.
Using a compklmentary pair of anti-gelonin BsAbs, one
targeting CD22 and the other CD38, we have produced a
complex which delivers gelonin to Daudi cells with an
efficiency which is close to that achieved by our best CD22
derivatives. Using the most effective pair of anti-CD38
BsAbs, gelonin toxicity could be increased about 11000
times over that of the free RIP. However, with a mixed pair
of BsAbs which target CD22 and CD38 simultaneously, we
have increased gelonin toxicity approximately 130000 times.
Thus, this cocktail is delivering gelonin with an efficiency
which is equal to that of the pair of anti-CD22 BsAbs. The
binding data confirm this intepretation, showing that, while aGeIomn dlmy f Iphm cb 1 ells
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pair of anti-CD38 BsAbs needs to capture 60 000 gelonin
molecules per cell to achieve half-maximum inhibition, the
anti-CD22/anti-CD38 BsAbs accomplished this with only
12 000 gelonin molecules per cell, a value which is very
similar to that given by the pair of CD22 BsAbs. Thus, by
binding CD22 and CD38 simultaneously we appear to gain
the advantages ofcapturing the RIP molecules bivalently and
internalising them with the efficiency of CD22. The most
likely explanation for this finding is that the anti-CD22 arm
of the anti-CD22/anti-CD38/gelonin complex is 'dragging' or
'piggy-backing' the CD38 molecules inside the cells. It may
be that the high density of CD38 on the target cells facilitates
the initial capture of the complex via its anti-CD38 arm with
subsequent binding of the anti-CD22 arm. For future patient
therapy, targeting dual antigens in the way described looks
very attractive. Antigen density on tumour cells will
effectively be increased, and variant cells which fail to express
one or other of the target antigens may be susceptible to
killing via the second.
We conclude that the targeting system which has been
developed for gelonin will complement the saporin system
which is currently being evaluated in clinical trials (Bonardi
et al., 1992). Because of its relative lack of toxicity, gelonin is
clearly an attractive RIP for human treatment and gives a
large therapeutic 'window' when targeted with BsAbs. In
addition, we anticipate being able to use BsAb-saporin and
BsAb-gelonin complexes in combination in individual
patients. Thus, when treatment with one RIP results in an
anti-RIP response, the RIP will be changed and the period of
treatment thereby extended.
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